Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma

1. Miguel, J.F.S.
2. Schlag, R.
3. Khuageva, N.K.
4. Dimopoulos, M.A.
5. Shpilberg, O.
6. Kropff, M.
7. Spicka, I.
8. Petrucci, M.T.
9. Palumbo, A.
10. Samoilova, O.S.
11. Dmoszynska, A.
12. Abdulkadyrov, K.M.
13. Delforge, M.
14. Jiang, B.
15. Mateos, M.-V.
16. Anderson, K.C.
17. Esseltine, D.-L.
18. Liu, K.
19. Deraedt, W.
20. Cakana, A.
21. Van De Velde, H.
22. Richardson, P.G.